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Abstract
Background: Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a
distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believed
to be related to immune dysregulations triggered by ICI can be serious and lead to treatment interruptions and in
severe cases, precipitate permanent discontinuation. Isolated neutropenia secondary to ICI has been rarely
documented in the literature and needs further description.
We report a case of pembrolizumab related severe isolated neutropenia in a patient with metastatic non-small cell
lung cancer. We were also able to obtain serial blood and plasma-based biomarkers for this patient during treatment
and during neutropenia to understand trends that may correlate with the irAE. In addition we summarize important
findings from other studies reporting on ICI related neutropenia.
Case presentation: A 74 years old Caucasian male treated with single-agent pembrolizumab for metastatic non-small
cell lung cancer presented with fevers, chills, and an isolated neutrophil count (ANC) of 0 2 weeks after the fourth dose.
In addition to antibiotics, due to the strong suspicion of this neutropenia being immune-mediated, he was started on 1
mg/kg of steroids and also received filgrastim to accelerate neutrophil recovery. Serial trends in C-reactive protein and
certain other inflammatory cytokines demonstrated a corresponding rise at the time of neutropenia. Post recovery, his
pembrolizumab was kept on hold. Eight weeks later he had a second episode of neutropenia which was again
managed similar to the first episode. Despite permanent discontinuation of ICI after the first neutropenia, his disease
showed an ongoing complete metabolic response on imaging. Our literature review reveals that hematological toxicities
constitute < 1% irAEs with isolated neutropenia roughly accounting for one-fourth of the hematological irAEs. Based on
the handful of ICI related neutropenia cases reported to date, we identified nivolumab to be the most common
offender. The median number of ICI cycles administered before presenting with neutropenia was three, and the median
time to recovery was approximately two weeks. All of these neutropenic episodes were≥ grade 3 and led to permanent
ICI discontinuation. Using immunosuppressive therapies in conjunction with granulocyte-colony stimulating factor was
the most common strategy described to have favorable results.
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Conclusion: Neutropenia as an isolated irAE secondary to ICI is rare but represents a severe toxicity that needs early
recognition and can often result in treatment discontinuations. Careful monitoring of these patients with the prompt
initiation of immunosuppressive and supportive measures to promote rapid recovery as well as prevent and treat
infectious complications should be part of the management algorithms. Serial monitoring of blood and plasma-based
biomarkers from more extensive studies may help in identifying patients at risk for irAEs and thus guide patient
selection for ICI.
Keywords: Immune checkpoint inhibitors, Neutropenia, Immune-related adverse event, C-reactive protein, IL-6,
Immunosuppression
Introduction
Due to their ability to modulate certain inhibitory path-
ways, immune checkpoint inhibitors (ICIs) promote a
T-cell mediated attack against tumor cells and thus
harness the immune system to generate anti-tumor
immunity. The recent advent of ICIs has radically
altered the treatment approaches and revolutionized
the outcomes for several tumor types that until recently
were known to have dismal outcomes [1]. Non-Small
Cell lung cancer (NSCLC) especially has witnessed a
paradigm shift with significant improvements in sur-
vival, response rates, and durability of disease control,
both in upfront and second line setting [2]. Based on
results from Keynote-024 [3], single agent pembrolizu-
mab was approved by the US Food and Drug Adminis-
tration in 2018 in the frontline treatment of metastatic
NSCLC having PD-L1 of ≥50%. Recently reported
updated results from this trial show a 16-month overall
survival benefit of pembrolizumab over platinum-based
chemotherapy in patients with previously untreated,
advanced NSCLC without EGFR/ALK aberrations. [4]
Compared to conventional chemotherapy, ICIs have
been noted to display distinct patterns of immune toxic-
ities, commonly labeled as immune-related adverse
events (irAEs). IrAEs differ from usual toxicities in terms
of having a more than likely immunological basis and
can have a broad spectrum of manifestations that can in-
volve different organ systems [5]. The incidence, distinct
tissue specificity, timing, and severity of irAEs are vari-
able and considered to be dependent on the type of ICI
antibody and underlying malignancy [6]. In general, data
from ICI related clinical trials and retrospective studies
have indicated the incidence of irAEs such as colitis,
pneumonitis, and thyroiditis to be higher compared to
nephritis, myocarditis, or myositis. The incidence of the
hematological adverse effects in general, and neutro-
penia, in particular, have rarely been documented as an
adverse event secondary to ICI, with an overall reported
incidence of < 1.0% [7]. A recent study that queried a
World Health Organization (WHO) pharmacovigilance
database (VigiBase) for ICI related hematological tox-
icities described autoimmune anemia and immune
thrombocytopenia as the most common hematologic
toxicities [8]. Conversely, a French pharmacovigilance
study reported neutropenic irAEs to account for
approximately one fourth (26%; n = 9/35) of all im-
mune hematological irAEs [9]. In addition to these
studies, to the best of our knowledge, there are nine
other individual cases of neutropenia-related to ICI
treatment published so far ([10–17]; Table 1).
We report a case of recurrent isolated severe neutro-
penia in a patient with metastatic adenocarcinoma of the
lung treated with pembrolizumab. Coincidentally we
were also able to obtain serial cytokine levels, and
peripheral T-cell counts for this patient during his treat-
ment and neutropenia as this patient was part of a study
cohort with institutional approval for a biomarker study
that allowed the collection of serial blood and plasma
for relevant translational studies (ECU IRB 16–000719).
Herein we also summarize essential findings from previ-
ously reported cases of neutropenia, discuss possible
mechanisms contributing to this toxicity and elaborate
briefly on management strategies that seem to work best
for this toxicity.
Case report
A 74-year-old Caucasian male with an Eastern Coopera-
tive Group performance status of 1 and a 150 pack -year
smoking history initially presented with progressive right
upper extremity weakness. Further workup revealed a
1.4 cm frontal lobe mass on magnetic resonance im-
aging. Computerized tomography (CT) of the chest
identified a spiculated mass lesion measuring 1.6 × 1.1
cm in the right hilar region. Apart from hypermetabolic
activity in the lung mass, a staging positron emission
tomography (PET) identified avidity in the mediastinal
and hilar lymph nodes. Biopsy of the lung mass and hilar
nodes identified moderately differentiated adenocarcin-
oma of lung origin. Based on this tumor size and nodal
involvement, his intrathoracic disease was staged as IIIA
(AJCC 7th). His solitary left precentral gyrus mass was
treated with gamma knife radiosurgery, and he was sub-
sequently placed on steroids with improvement in his
limb weakness. His intrathoracic disease was treated
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with four cycles of cisplatin and pemetrexed with
concurrent definitive radiation therapy. During follow-
up, a surveillance PET scan approximately 11 months
later was notable for new metastatic liver, mediastinal,
para-aortic and right lower lobe lesions. Due to his
original biopsied tissue having PD-L1 expression of 50%
(22c3 antibody), he was started on single agent pembro-
lizumab 200 mg every 3 weeks. His baseline blood counts
before starting pembrolizumab were all within the
normal range. Two weeks after completing the fourth
cycle of pembrolizumab, he presented to the emergency
department with fever, chills, and general malaise. He
was noted to be neutropenic with an absolute neutrophil
count (ANC) of 0, which previously was noted to be
normal the day of his fourth dose of pembrolizumab
(Fig. 1). Hemoglobin was 12.6 g/dl, and platelet count
was normal. The patient was hospitalized with febrile
neutropenia and started on broad-spectrum antibiotics.
As part of our programmatic approach, a serum C-
reactive protein (CRP) level was obtained, which was
markedly elevated at 175.4 mg/L (Fig. 1). He was started
on prednisone 80mg daily and filgrastim dose of 5 mcg/
kg daily for 4 days. All his infectious workup, including
blood cultures, were negative. Bone marrow biopsy
showed normocellular marrow with left-shifted trilineage
hematopoiesis, with a predominance of early erythroid
and myeloid precursors and no increase in blasts or
significant morphologic dysplasia. Cytogenetics and
myelodysplastic syndrome panel were normal. His ANC
started to improve by day four of prednisone and filgras-
tim (Fig. 1). From his serial blood samples, he also had
T-cell counts and cytokines checked (Fig. 2). He had
complete recovery of his neutrophil count with ANC of
2400/ μL by day six of admission. Computerized Tom-
ography imaging of the chest done during admission
showed intrathoracic disease response compared to the
CT performed 6 weeks earlier. His steroid taper sched-
ule was 80mg daily for week 1, 40 mg daily for week 2,
20 mg daily for week 3, 10 mg daily for week 4 and then
stopping. His pembrolizumab was kept on hold.
However, eight weeks after being discharged, he was
readmitted again with fever, cough, and shortness of
breath. He was again noted to be neutropenic with ANC
of 0 / μL (Fig. 1). Other complete blood count parameters
Fig. 1 Graph showing the trend of the ANC and CRP for the first and second episode of neutropenia. 1D0 = Day 0 for first neutropenic episode, 2
D0 = Day 0 for second neutropenic episode. Corresponding days are measured based on days from the first neutropenic episode (1D0) and day of
the second neutropenic episode (2D0). Note rise in CRP corresponds to fall in ANC in both instances. ANC improved with the use of filgrastim daily
for 4 days at the first neutropenic episode and one dose of pegfilgrastim with the second neutropenic episode. Steroid taper for the first neutropenic
episode was completed on day + 28 from neutropenia onset. ANC recovery in both episodes was observed 4 to 5 days from neutropenia onset
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were within the normal range. His CRP had again
increased to 43.5mg/L, from 7.7mg/L at the last clinic
visit 6 weeks prior. He was started on broad-spectrum
antibiotics, prednisone 1mg/kg, and a single dose of peg-
filgrastim. Viral studies (HIV, Hepatitis-B, Hepatitis-C,
and CMV) were negative. EBV IgG and Parvovirus B19
IgG titers were elevated and thus consistent with prior
infection. Antinuclear antibodies (ANA), antineutrophil
cytoplasmic antibodies (ANCA), rheumatoid factor (RF),
and neutrophil-associated antibodies were negative, and C3
and C4 levels were normal. His neutrophil counts recov-
ered to > 1500 on day seven of the second hospitalization.
His neutrophil counts were 5440/ μL at his post-
discharge clinic follow up a week later. A restaging PET
scan showed continued response with some areas of
complete metabolic response. He continued prednisone
taper for 8 weeks. Although his ANC showed persistent
recovery and remained > 5000 / μL after his second
hospitalization, his pembrolizumab was kept on hold.
Repeat PET scan 7 weeks after the second neutropenia
showed the metabolic activity of a mass like consolida-
tion with air bronchogram in the posterior right upper
lung and moderate focal uptake in the enlarged portoca-
val lymph node and tiny periaortic lymph nodes suggest-
ing recurrent malignancy with likely a post-obstructive
pneumonia. Unfortunately, despite adequate outpatient
management, he had recurrent episodes of bacterial
pneumonia complicated by hospitalizations due to which
his performance status declined considerably. Due to
this, he could not be initiated on any further treatment.
Three months after his second neutropenic episode, he
died from hypoxemic respiratory failure secondary to
bacterial pneumonia that was unrelated to ICI use or
neutropenia.
Discussion
Neutropenia, as an irAE secondary to ICI is a rare find-
ing with no comprehensive reports or clear management
guidelines published to date. Here we discuss a unique
case of isolated neutropenia secondary to ICI and also
summarize previously reported cases with similar find-
ings published in the literature. The absence of con-
founders, such as recent chemotherapy or medications
that can cause cytopenias strongly supports our diagno-
sis of ICI as the primary etiology for the neutropenia.
Furthermore, from a biomarker standpoint, we have also
attempted to correlate serial inflammatory markers
derived from blood and plasma with the ICI treatment
course and the occurrence of neutropenia, an aspect that
has not been documented to date.
Although immunotherapy has revolutionized the man-
agement of several tumor types, the occurrence of irAEs
as a side effect can lead to significant morbidity as well as
premature treatment discontinuations. Currently, the
putative relationship between anti-tumor immunity and
irAEs is not well understood. IrAEs are believed to be re-
lated to ICI mediated alterations in the roles that immune
checkpoints play in maintaining immunologic homeosta-
sis leading to the generation of auto-inflammatory
responses [18]. Thus irAEs are more likely to reflect an
Fig. 2 Cytokine concentration during the treatment course and at the time of neutropenia. Post-C4 levels are not displayed as the patient was
admitted two weeks after C3, i.e., prior to C4 sample collection. Compared to baseline, a significant rise in IL-6, IL-10 and IL-17 are seen at the
point of irAE. These co-relate with rise in CRP (Fig. 1). Two weeks post irAE, IL-6 and IL-17 levels demonstrate a downtrend while IL-10 level was
noted to be rising. Sample collection at neutropenia was a day after treatment with steroids. Hence the treatment effect cannot be
entirely excluded.
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exaggerated host immune function. Both auto-reactive T-
cell and antibody-mediated processes have been specu-
lated to mediate irAEs [6]. These theories are supported
by some emerging data demonstrating T-cell clone cross-
reactivity with antigens/epitopes shared between tumors
and healthy tissue in patients presenting with irAEs [19,
20]. Also, alterations in various B-cell subsets correlating
with timing and incidence of irAEs has been observed
[21]. Similar to other irAEs, the mechanisms proposed for
hematologic toxicities include generation of autoreactive
T and B-cells as well as a decrease in T-regulatory pheno-
type [7].
The first neutropenia occurrence in our patient was
after 4 cycles of pembrolizumab. This is similar to other
reported cases (Table 1) where the median time to onset
of neutropenia was after 3 cycles (range 2–11). Based on
our literature review, the median time to onset of
hematological toxicities has been noted to be shorter for
anti-CTLA-4 monotherapy or the combination anti-
CTLA-4/anti-PD-1 therapy compared to anti-PD-1 ther-
apy alone [8]. In a majority of the cases we have
reported (Table 1), and in nine other patients in the
French study [9], nivolumab was the most common ICI
resulting in neutropenia. However, given the limited
number of patients, establishing a causal relationship
between a specific ICI and neutropenia is not possible.
A significant majority of documented cases (Table 1),
including data reported from the French registry, were
grade-4. Per the French study, more than 60% of isolated
neutropenias were associated with febrility, which corre-
sponds to our patient’s presentation [9]. Most of the
patients in the previously published cases had other
concurrent irAEs that manifested as rash, hepatitis, and
colitis (Table 1). Based on data from 168 hematological
toxicities observed in the WHO VigiBase, around 23%
had concurrent non-hematological toxicities [8]. Our
patient, however, presented with isolated neutropenia
and no other accompanying irAEs. Due to the scarcity of
data on ICI related neutropenia, for now, it is unclear
which concurrent non-hematological irAEs have a stron-
ger association with neutropenia and whether outcomes
differ among these irAE subsets.
Due to the severity of the index neutropenic event,
neither our patient nor any of the other reported
patients were resumed on ICI. This permanent discon-
tinuation of ICI broadly conforms to recent treatment
guidelines for irAEs published by the American Society
of Clinical Oncology where all leukopenias have been
grouped as a single entity [22]. Intriguingly, our patient’s
course was complicated by a recurrence of severe neu-
tropenia despite holding ICI and complete resolution of
the first neutropenic episode. Although evidence from
literature supports that a majority irAEs occur within
the first 5–15 weeks of starting ICI, similar to our case
there are some reports of late-onset toxicities both in
the setting of ongoing immunotherapy and after stop-
ping treatment [23, 24]. Durable responses have been
linked to ICI induced persistent CD8+ T effector mem-
ory subset against tumor cells [25]. The potential cross-
reactivity of these T-cells against normal tissue after
stopping treatment is one of the plausible mechanisms
that has been suggested to contribute to this phenomenon
[18]. In addition, following infusion anti-PD-1 antibodies
have a prolonged receptor occupancy of > 2months on T-
cells and a half-life that spans three to four weeks with a
steady state concentration achieved in 19 weeks [26, 27].
We speculate all these factors in conjunction contributed
to the delayed recurrence of neutropenia in our patient. A
two-month post neutropenia PET in our patient showed
ongoing near complete metabolic response despite treat-
ment discontinuation. This ongoing response despite
stopping pembrolizumab after neutropenia conforms to
the premise of emerging data suggesting that irAEs may
act as a marker of ongoing anti-tumor activity and benefit
from ICI [28]. However, the patient passed away due to
unrelated hypoxemia secondary to pneumonia.
Bone marrow evaluation of our patient did not reveal
involvement with the underlying malignancy but demon-
strated a normocellular marrow with left-shifted triline-
age hematopoiesis. A majority of previously reported
cases also underwent bone marrow biopsy demonstrat-
ing variable findings (Table 1). Our findings of a normo-
cellular BM in the setting of severe neutropenia raises
suspicion of ICI induced peripheral destruction of neu-
trophils. However, given the limited scope of our sero-
logical and biomarker studies, we could not establish if
this were a T-cell or an antibody driven process. Never-
theless, in the context of ICI induced cytopenias that
persist despite treatment discontinuation and immuno-
suppressive strategies, it is essential to rule out bone
marrow etiologies, including obtaining genetic panels for
myeloid disorders, especially in the elderly.
Elevation in C-reactive protein (CRP) with neutropenia
and subsequent fall with neutropenia resolution was a
unique observation in our patient. We have previously
reported on findings of elevations in CRP during irAEs
compared to baseline levels before starting ICI [29].
Furthermore, we have also shown elevated levels of
interleukin-6 (IL-6) corresponding to elevated CRP in a
patient with pneumonitis [30]. This observation was
again reproduced in the current patient where neutro-
penia corresponded to an elevation of not only IL-6 but
also elevations in IL-17 and IL-10 levels (Fig. 2)
compared to baseline. Altered levels of baseline cyto-
kines/chemokines, including IL-6/IL-10, have also been
described by others where lower baseline levels followed
by a subsequent increase during treatment was seen in
patients with irAEs [31]. Furthermore we have recently
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reported on the use of tocilizumab, an anti-IL-6 receptor
antibody in the context of steroid-refractory irAEs,
where we observed a significant benefit in terms of reso-
lution of irAE symptoms and duration of hospitalization
[32]. Although these observations are indirectly suggest-
ive of altered cytokine physiology in promoting an im-
mune dysregulation during irAEs, prospective validation
to account for confounding etiologies (potential infec-
tion in our patient) that can contribute to dysregulation
of cytokines is required. It is also important to note that
both CD4 and CD8 cell counts were higher on the post-
cycle-3 blood draw compared to post-cycle-2 (Fig. 3). A
sustained and early rise in tumor-specific CD8 has been
seen to co-relate with benefit from ICI [33]. This makes
an argument that in addition to denoting ICI benefit, a
rise in specific T-cell subsets beyond a critical threshold
compared to baseline or significant alterations between
subsequent cycles could be a marker for impending im-
mune dysregulation leading to irAE. Thus understanding
the relationships between T-cell subsets, cytokines, and
irAEs in larger cohorts could be critical in identifying
biomarkers for early detection of irAEs and choosing
optimal candidates for ICI.
Due to its rarity, the optimal management strategy for
ICI-related neutropenia is not established. As with most
irAEs, response to immunosuppression after stopping the
ICI has been documented in most of the published case
reports (Table 1). Various combinations of high-dose ster-
oidal and non-steroidal immunosuppression (cyclospor-
ine, anti-thymocyte globulin, and mycophenolate mofetil)
in addition to G-CSF or IVIG have been used to manage
ICI-related neutropenia (Table 1). Despite some concern
due to the potential of exacerbating underlying bacterial
or fungal infections, steroid use has been consistently
reported as part of initial management of ICI induced
neutropenia. We recommend a slow tape of steroids after
the index event to decrease chances of cyclic/recurrent
exacerbation of neutropenia even after ICI has been
discontinued. Thus, initiating prompt treatment can help
in reducing the duration of neutropenia and thus prevent
potentially life-threatening consequences.
Conclusion
With rapid advances in the field of immuno-oncology
and frequent use of newer ICI for multiple indications,
we speculate that the potential for encountering unique
irAEs secondary to ICI will rise. Our case adds to the
growing body of evidence alluding to the unique im-
mune adverse effect profiles of ICI. Evidence from our
review establishes that ICI related neutropenia, although
rare, tends to be severe, with a majority being grade-4.
These immune-mediated neutropenias can lead to
significant morbidity and mortality arising from infec-
tious complications. Permanent ICI discontinuation
needs to be strongly considered in almost all patients.
Hence ICI related neutropenia as an irAE requires early
identification with prompt interventions using immune
suppression and granulocyte colony-stimulating factors
to perhaps mitigate duration and thus prevent poten-
tially fatal outcomes.
Fig. 3 Changes in CD-4 and CD-8 cell counts during immunotherapy. Serial CD4/CD8 T –cell counts were obtained from peripheral blood and are
plotted on a Log10 scale showing changes during immunotherapy course. Post-C2 refers to the sample collected on the day of C3 day-1 before anti-
PD-1 administration. Post C3 refers to the sample collected on the day of C4 day-1 before anti-PD-1 administration and also represents the sample
obtained prior to hospitalization due to neutropenia. Post-C3, when compared to post-C2, was noted to have a 1.2 and 1.5 fold increase for CD8 and
CD4 counts, respectively. Drop in CD4/CD8 cell counts at neutropenia was likely because the in-hospital sample collection was after treatment with
immunosuppression. Post neutropenia sample collection was at clinic follow up after discharge
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